Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 5,476–5,500 of 27,380 studies, newest first · page 220 of 1096.

January 2025 25

  1. 2025-01-21

    Development of an Evidence-Based Cognitive Training Application for Elderly Individuals with Cognitive Dysfunction

    ✓ Peer-reviewed Prevention trials Healthcare

    Key finding: The application was developed with distinct user and administrator interfaces to support engagement and monitoring. +4 more findings

  2. 2025-01-21

    Changes in the Parietal Lobe Subregion Volume at Various Stages of Alzheimer’s Disease and the Role in Cognitively Normal and Mild Cognitive Impairment Conversion

    ✓ Peer-reviewed Mild cognitive impairment Journal of Integrative Neuroscience

    Key finding: The left inferior parietal lobule (IPL)_6_5 (rostroventral area 39) showed the best ability to discriminate between patients with AD and those with CN (AUC = 0.688). +4 more findings

  3. 2025-01-21

    Blood Neurofilament Light Chain and Phospho-Tau 181 in Subjects with Mild Cognitive Impairment Due to Age-Related Hearing Loss

    ✓ Peer-reviewed Mild cognitive impairment Journal of Clinical Medicine

    Key finding: Patients with hearing impairment presented slightly altered results on cognitive tests, typical of a mild cognitive impairment. +3 more findings

  4. 2025-01-21

    Distinct subcellular localization of tau and alpha-synuclein in lewy body disease

    ✓ Peer-reviewed Lewy body dementia Acta Neuropathologica Communications

    Key finding: The abundance of p-α-syn, p-tau, and MHCII was significantly associated with diagnosis of LBD. +2 more findings

  5. 2025-01-21

    Explainable machine learning models for identifying mild cognitive impairment in older patients with chronic pain

    ✓ Peer-reviewed Digital health tools BMC Nursing

    Key finding: Age, education level, number of pain sites, pain duration, pain level, depression and sleep quality were risk factors of MCI in older patients with chronic pain. +4 more findings

  6. 2025-01-21
  7. 2025-01-21

    Global Burden of Alzheimer’s Disease and Other Dementias during 1990–2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study

    ✓ Peer-reviewed How common it is Neuroepidemiology

    Key finding: The global age-standardized prevalence of AD and other dementias increased from 672 (95% uncertainty interval: 589 to 764) per 100,000 population in 1990 to 694 (603 to 794) per 100,000 population in 2021, with AAPCs of 0.09% (95% confidence interval: 0.06% to 0.11%). +4 more findings

  8. 2025-01-21

    Closing the gap in dementia research by community-based cohort studies in the Chinese population

    ✓ Peer-reviewed Getting a diagnosis The Lancet Regional Health - Western Pacific

    Key finding: China accounts for 1/5 of the global population and China faces a particularly heavy dementia burden due to its rapidly ageing population. +3 more findings

  9. 2025-01-21

    Lessons from the Implementation of the Sendai Framework for Disaster Risk Reduction from Latin America and the Caribbean

    ✓ Peer-reviewed Prevention and risk International Journal of Disaster Risk Science

    Key finding: Over the past decade, Latin America and the Caribbean (LAC) have made progress in implementing the Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR).

  10. 2025-01-21

    Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition

    ✓ Peer-reviewed Biomarkers Neurology

    Key finding: Among 463 ADNI participants with baseline MCI (mean age 72.6 ± 7.3 years, 43.4% female), the OSA PRS, adjusted for BMI, was significantly associated with MCI-to-AD progression. +4 more findings

  11. 2025-01-20

    Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine

    ✓ Peer-reviewed Treatments Dementia and neurocognitive disorders

    Key finding: Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. +4 more findings

  12. 2025-01-20

    Mapping the effectiveness and risks of GLP-1 receptor agonists

    ✓ Peer-reviewed Risk factors Nature medicine

    Key finding: We used a discovery approach to systematically map an atlas of the associations of GLP-1RA use versus each comparator with 175 health outcomes. +3 more findings

  13. 2025-01-20

    Communicative intentions and liminal signs in interaction with people living with late-stage dementia

    ✓ Peer-reviewed Brain tissue and pathology Journal of Pragmatics

    Key finding: Drawing on Goffman's distinction between "giving" and "giving off" information and Grice's theory of communicative intentions, we analyze interaction sequences where caregivers may or may not notice and respond to these signs. +4 more findings

  14. 2025-01-20
  15. 2025-01-20

    Estimation of Machine Learning–Based Models to Predict Dementia Risk in Patients With Atherosclerotic Cardiovascular Diseases: UK Biobank Study

    ✓ Peer-reviewed Digital health tools JMIR Aging

    Key finding: The findings of this study suggest that predictive modeling could inform patients and clinicians about ASCVD at risk for dementia. +2 more findings

  16. 2025-01-20

    An interpretable machine learning tool for in-home monitoring of agitation episodes in people living with dementia: a proof-of-concept study

    ✓ Peer-reviewed Digital health tools EClinicalMedicine

    Key finding: Light Gradient-boosting Machine (LightGBM) achieved the highest performance in identifying agitation over an 8-day period with a sensitivity of 71.32% ± 7.38 and specificity of 75.28% ± 7.38. +4 more findings

  17. 2025-01-20

    A European-Multicenter Network for the Implementation of Artificial Intelligence to Manage Complexity and Comorbidities of Atrial Fibrillation Patients: The ARISTOTELES Consortium

    ✓ Peer-reviewed Digital health tools Thrombosis and Haemostasis

    Key finding: In the prospective GLORIA-AF registry of AF patients, the presence of clinical complexity was associated with lower odds of being prescribed with OAC (odds ratio [OR] 0.50, 95% confidence interval [CI] 0.44–0.57), higher OAC discontinuation, and with a higher risk of adverse events (hazard ratio [HR] 1.63, 95% CI 1.43–1.86).[ 4 ] Indeed, “high clinical complexity” patients defined using latent class analysis constituted 6.6% of AF patients, and was associated with higher hazards of experiencing the primary composite outcome of all-cause death and major adverse cardiovascular events (HR 1.47, 95% 1.24–1.75).[ 5 ] Comorbidities and polypharmacy have an important influence on decision-making, by conditioning either lack of prescription of OAC in patients at risk or inappropriate dosing.[ 6 ] [ 7 ] [ 8 ] Recognizing that AF management is more than simply OAC alone, and requires a holistic and integrated care approach, contemporary guidelines globally on AF management have promoted this concept, based on the Atrial fibrillation Better Care (ABC) pathway, emphasizing Anticoagulation, Better symptom management with rate or rhythm control, and Comorbidity/lifestyle management.[ 9 ] [ 10 ] [ 11 ] The ABC pathway is well supported by clinical trial and real-world evidence,[ 11 ] whereby adherence to the ABC pathway is associated with a reduction in all-cause and cardiovascular mortality, stroke, and bleeding.[ 12 ] [ 13 ] Despite this, adherence to ABC-based management remains low, whereby a meta-analysis of 14 studies revealed that only 21% (95% CI 13–34%) of AF patients were managed in accordance with the ABC pathway.[ 12 ] This perhaps highlights a critical gap in the implementation of comprehensive evidence-based care strategies. +1 more finding

  18. 2025-01-20

    Disparity in attitudes regarding assisted dying among physicians and the general public in Japan

    ✓ Peer-reviewed Disparities BMC Medical Ethics

    Key finding: The findings revealed that Japanese physicians did not display support for euthanasia (2%) and assisted suicide (1%); however, the general public supported euthanasia (33%) and assisted suicide (34%). +4 more findings

  19. 2025-01-20

    Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction

    ✓ Peer-reviewed Prevention and risk Journal of Clinical Medicine

    Key finding: Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. +3 more findings

  20. 2025-01-20
  21. 2025-01-18

    Middle-age cerebral small vessel disease and cognitive function in later life: a population-based prospective cohort study

    ✓ Peer-reviewed Vascular contributions The Lancet Regional Health - Western Pacific

    Key finding: Of the total, 908 (37.0%) participants had cSVD on MRI reading at baseline. +4 more findings

  22. 2025-01-18
  23. 2025-01-18
  24. 2025-01-18

    The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts

    ✓ Peer-reviewed Lewy body dementia Neuroscience

    Key finding: In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.

  25. 2025-01-18

    Alterations of amino acids in older adults with Alzheimer’s Disease and Vascular Dementia

    ✓ Peer-reviewed Risk factors Amino Acids

    Key finding: Several differences in the concentration of amino acids were observed in AD patients compared to both healthy controls and VD patients. +2 more findings

Browse the library by subject, with the full score breakdown →